European Consortium Launches 13 Million Euro Initiative for Regenerative Joint Therapy
Scaling Production for Global Clinical Standards
Exogenus Therapeutics is spearheading a new international consortium to develop advanced secretome therapies for osteoarthritis patients. The project, titled ExoCordOA, has secured 13 million euros in funding through the Horizon Europe program. Over the next five years, ten partner organizations will collaborate to move these innovative biological treatments toward clinical application.
The initiative focuses on extracellular vesicle-enriched secretomes, which are substances secreted by cells that can trigger healing. By utilizing these biological components, researchers hope to create a new class of regenerative medicine. This approach could potentially repair damaged joint tissue rather than just managing the chronic pain associated with the condition.
A major hurdle in regenerative medicine is the ability to manufacture complex biological products at a large scale. The consortium includes industry giants like Lonza and specialized institutions such as the Anthony Nolan trust to address these logistical challenges. These partners will work to standardize the production of secretomes derived from umbilical cord blood.
Can Secretomes Replace Traditional Surgery?
Regulatory compliance is also a core focus of the five-year plan. Eliquent Life Sciences and various academic institutions, including Utrecht University, will ensure the development process meets strict safety guidelines. By integrating artificial intelligence through partners like iLoF, the team aims to streamline patient selection and treatment monitoring.
Current treatments for severe osteoarthritis often rely on invasive joint replacements or temporary pain relief injections. This project seeks to determine if secretome therapy can offer a non-surgical alternative that restores mobility. If successful, the technology could be adapted to treat other inflammatory and degenerative diseases beyond joint health.
The collaboration represents a significant investment in European biotechnology and patient care. By the end of the five-year period, the group intends to have a validated therapeutic candidate ready for human trials. This milestone would mark a shift toward more accessible and effective regenerative therapies for millions of aging citizens.
Frequently Asked Questions
What is the primary goal of the ExoCordOA project? The project aims to develop a new therapy for osteoarthritis using extracellular vesicles and secretomes. It seeks to create a standardized, scalable treatment that can regenerate damaged joint tissues.
Which organizations are involved in this research? The consortium is led by Exogenus Therapeutics and includes ten partners such as Lonza, Anthony Nolan, and Utrecht University. These groups provide expertise in manufacturing, blood research, and regulatory strategy.
How long will it take to see results from this funding? The Horizon Europe grant covers a five-year development period focused on refining the therapy and preparing for clinical trials. The team will spend this time establishing manufacturing protocols and proving the treatment's safety.